Deli Hoda, Vakili-Ghartavol Zeynab, Asgari Yazdan, Tavoosidana Gholamreza, Eftekhar Ebrahim, Ghahremani Mohammad Hossein
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
BMC Cancer. 2025 Jan 9;25(1):46. doi: 10.1186/s12885-024-13392-2.
Colorectal cancer (CRC) is a common gastrointestinal cancer, and even though oxaliplatin chemotherapy is effective, there is a high likelihood of relapse, indicating the presence of oxaliplatin-resistant CRC. Therefore, it is crucial to comprehend the molecular mechanisms of oxaliplatin resistance and develop effective strategies to counter drug resistance. Numerous studies have demonstrated the close association between microRNAs (miRNAs) and drug resistance in CRC. In this study, we aimed to identify the essential exosomal and cellular miRNA related to oxaliplatin resistance in the CRC cell line HCT-116.
The miRNA expression profile of CRC cells with resistance to oxaliplatin was analyzed. The effectiveness of diagnostics and biomarker potency of miRNAs were evaluated by receiver operating characteristic (ROC) analysis. Target miRNAs were identified, and the enrichment analysis was assessed based on Gene Ontology (GO), Reactome, and Human Disease Ontology (DO). In vitro experiments, oxaliplatin-resistant HCT-116 cells (HCT116-OXA) were developed, and the exosomes were isolated and characterized from HCT116-OXA and HCT116 cells. The expression of the selected miRNAs was evaluated in HCT116-OXA cells and their exosomes, and they were compared to HCT-116 cells using quantitative real-time PCR.
This study revealed that a combination of miR-4326, miR-3615, miR-7974, miR-130b-3p, and miR-454-3p exhibited the highest area under the curve (AUC), sensitivity, specificity, and superior diagnostic and predictive performance. In vitro experiments, HCT116-OXA cells displayed reduced early and late apoptosis, a bypass of S phase arrest, prolonged doubling time, and higher IC compared to parental cells. The expression of miR-454-3p, miR-130b-3p, miR-7974, miR-3615, and miR-4326 was decreased in HCT116-OXA cells as compared to sensitive cells. However, a significantly higher expression of miR-130b-3p and miR-4326 was observed in the isolated exosomes of HCT116-OXA cells as compared to the sensitive cells.
The low expression of miR-454-3p, miR-7974, and miR-3615 in CRC cells or high expression of miR-130b-3p and miR-4326 in isolated exosomes could predict the response to oxaliplatin therapy. This indicates the potential of these specific miRNAs to serve as predictive markers for the response to oxaliplatin therapy.
结直肠癌(CRC)是一种常见的胃肠道癌症,尽管奥沙利铂化疗有效,但复发可能性很高,这表明存在对奥沙利铂耐药的结直肠癌。因此,了解奥沙利铂耐药的分子机制并制定有效的抗耐药策略至关重要。众多研究已证明微小RNA(miRNA)与结直肠癌耐药之间存在密切关联。在本研究中,我们旨在鉴定与结直肠癌细胞系HCT-116中奥沙利铂耐药相关的关键外泌体和细胞miRNA。
分析对奥沙利铂耐药的结直肠癌细胞的miRNA表达谱。通过受试者工作特征(ROC)分析评估miRNA的诊断有效性和生物标志物效力。鉴定靶miRNA,并基于基因本体论(GO)、Reactome和人类疾病本体论(DO)进行富集分析。在体外实验中,构建对奥沙利铂耐药的HCT-116细胞(HCT116-OXA),并从HCT116-OXA和HCT116细胞中分离和鉴定外泌体。使用定量实时PCR评估所选miRNA在HCT116-OXA细胞及其外泌体中的表达,并与HCT-116细胞进行比较。
本研究表明,miR-4326、miR-3615、miR-7974、miR-130b-3p和miR-454-3p的组合表现出最高的曲线下面积(AUC)、敏感性、特异性以及卓越的诊断和预测性能。在体外实验中,与亲代细胞相比,HCT116-OXA细胞表现出早期和晚期凋亡减少、S期阻滞绕过、倍增时间延长以及更高的IC。与敏感细胞相比,HCT116-OXA细胞中miR-454-3p、miR-130b-3p、miR-7974、miR-3615和miR-4326的表达降低。然而,与敏感细胞相比,在HCT116-OXA细胞分离的外泌体中观察到miR-130b-3p和miR-4326的表达显著更高。
结直肠癌细胞中miR-454-3p、miR-7974和miR-3615的低表达或分离外泌体中miR-130b-3p和miR-4326的高表达可预测对奥沙利铂治疗的反应。这表明这些特定miRNA有潜力作为奥沙利铂治疗反应的预测标志物。